Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
i remember you from vitra
we all
made money
Yup. Seem to find em all.
ugh
Another scam
WTF
Scam. All shareholders continues to get screwed.
Whoops, I did it, again
Pharma Two B Announces Plans to Go Public via Merger with Hepion Pharmaceuticals, Inc. and Concurrent $11.5 Million Private Placement
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
Any thoughts on whether they could see accelerated approval now? results were good and there are no good alternatives.
What if it is a lush partnership instead?
Absolutely correct, sir
Don't forget it's a delinquent stock has failed to meet requirements ie r/s to raise more funds rinse and repeat for at least another 3 years and if one bad thing happens expect a 90% haircut immediately imho
people DUMPING knowing the OFFERING is imminent…
GOOD CALL: after R/S This could be a moon shot on good top line results
#HEPA ?? 117% move today! Looking strong and ready for tomorrow! $HEPA
R/S, huge double digit negative returns, burning capital, zero Profitability
Management Effectiveness
Return on Assets -42.63%
Return on Equity -78.41%
Cash Flow Statement
Operating Cash Flow -33.05M
Levered Free Cash Flow -16.86M
Profitability
Profit Margin. 0.00%
Operating Margin 0.00%
Yahoo
It is losing/spending more than its market cap. Imho will fade back to singles and dilute. It can't keep operations running without selling shares to share holders.
Yes (for up to $350 million)
and Yes (check the latest 10Q - very little cash left on hand)
DO THEY HAVE A SHELF OFFERING TO DRAW FROM?
ARE THEY CURRENTLY IN NEED OF CASH FROM AN OFFERING?
Call wrong baby ....Biden say No more offering.... inflation is extremely now
Offering tonight or tomorrow. Called it
Might jus do it
Gotta bust thru 16.40 and hold it
$HEPA : Meeting those PRIMARY ENDPOINTS
Another MDGL kinda booster about to happen here.... now $15
GO $HEPA
This is not even .80c PS. Whose selling?
Achieves primary and secondary endpoints its all good
https://finance.yahoo.com/news/hepion-pharmaceuticals-phase-2-altitude-110000500.html
Will Pre-market trading be suspended ?
830 am
Monday’s conference call update
after R/S This could be a moon shot on good top line results
But it all. Taking knife. We are scammed.
$HEPA: So the RS happened........ now $9
But on a downdip........... will have to get some more if this dips sub $9
GO $HEPA
Your shares look like crap like the rest of us!! Pumper
I'd consider getting back at .36
Good thing you dumped this dog.
Pumper come back. Where have you been? We need another boost and lecture. Pumper rah rah rah.
Just added some SAB members. Lets see if we finally get some real info.
Maybe they need a new CEO
Followers
|
80
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2150
|
Created
|
12/18/14
|
Type
|
Free
|
Moderators |
Hepion Pharmaceuticals (Nasdaq: $HEPA) is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV).
Hepion announced top line data from the low dose cohort in the Company's Phase 2a ‘AMBITION' clinical trial of CRV431, an oral, once daily novel cyclophilin inhibitor. This Phase 2a study is continuing with the higher dose of 225 mg CRV431, with NASH patient dosing expected to be completed in Q1-2021.In 2021, of the more than 300 million people living with HBV infection, 10.5% (27 million) were aware of their infection. Non-alcoholic Fatty Liver Disease (NAFLD) affects up to 25% of people in the United States. There are currently no medicines that can cure non-alcoholic Fatty Liver Disease effectively. The same can be said with HBV. With the momentum growing around hepatitis B drug discovery research, we are closer than ever to a cure.
Fact: The inflows have been massive the last 2 weeks. Reason why In just 28 days at the low dose, HEPA CRV431 results were as good as what Madrigal's P3 lead NASH drug took 12 weeks to accomplish.
Bottom line The FDA looks for safety first we have the safest NASH drug our efficacy data is better than MDGL & AKRO. there market caps our almost 10x HEPA. Smart savvy biotech investors with deep pockets know this and are accumulating all they can of HEPA at these levels.
One morning we can wake up and see the price has tripled from its 160 market cap. Also they have 120 million in cash burning under 5 million a quarter. Lots of moving parts here. Gilead & Novo in the mix we will see? A new molecule being added to the pipeline. This management team is experienced 100 years total and world renown experts on cyclophilin inhibitors. They brought a FDA approved blockbuster drug to market already.
June 2021 Hepa Biz Presentation
https://hepionpharma.com/wp-content/uploads/2021/06/Corporate-deck-June-2021-FINAL.pdf
HEPA AI-POWR
https://hepionpharma.com/ai-powr/
HEPA Tackling Chronic Liver Disease - CRV431 Mechanism of Action
https://www.youtube.com/watch?v=CE7es4l1avM
HEPA GLOBAL NASH CONFERENCE PRESENTATION:
https://12ewye24eigk3g5kwa2dxjzm-wpengine.netdna-ssl.com/wp-content/uploads/2021/04/4thGlobal_NASH_Congress_Draft_20Apr2021_FINAL-1.pdf
HEPA website
https://hepionpharma.com
Chairman of the Board, Gary Jacob, is not just a business guy, he's one hell of a biochemist, and you can bet he has a solid grasp of everything that's going on with Hepion.
He's a key player here!
His background goes way beyond what you ordinarily see on the BOD of little R&D biotechs. You might see those with his research background on Scientific Advisory Boards, but they wouldn't have a fraction of the business expertise he's got.
Hepion has the whole package, with this guy!!
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
https://www.globenewswire.com/news-release/2019/08/07/1898563/0/en/Hepion-Pharmaceuticals-Welcomes-Dr-Stephen-Harrison-to-its-Scientific-Advisory-Board.html
Former Novo Nordisk Executive, Dr. Todd M. Hobbs, Joins Hepion Pharmaceuticals as Chief Medical Officer
Todd Hobbs coming to Hepion. It was published in December. Hobbs' primary focus has always been on diabetes, and I have said many times that there's a blockbuster reason for him leaving his position as Vice President, Chief Medical Officer at Novo Nordisk, a USD 190B global pharmaceutical behemoth, after nearly 17 years there, to come to tiny Hepion.
I believe we'll be hearing about CRV431 in the treatment of diabetes, as it has the highest known potency of any reported cyclophilin inhibitor known, by a wide margin...
https://www.biospace.com/article/releases/former-novo-nordisk-executive-dr-todd-m-hobbs-joins-hepion-pharmaceuticals-as-chief-medical-officer/
Nash Phase 2 & 3 Trials by companies in the space:
AKRO Akero Therapeutics 1.1 Billion Marketcap 240 Million in cash
MDGL Madrigal Pharmaceutical 1.7 Billion Marketcap 300 Million in cash
HEPA Hepion Pharmaceuticals 160 Million market cap 120 million in cash
Currently trading at $2.2 due to a public offering of 44.000.000 shares $2
According to analysts' consensus price target of $80.00, Hepion Pharmaceuticals has a forecasted upside of 3,503.6% from its current price of $2.22.
$HEPA
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |